Literature DB >> 3286764

Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses.

R Hirsch1, M Eckhaus, H Auchincloss, D H Sachs, J A Bluestone.   

Abstract

Anti-T3 mAb are being increasingly used clinically in the treatment of organ graft rejection. However, there has not previously been a murine model in which the effects of these mAb on the immune system could be studied in vivo. We have established such a model using the anti-murine-T3 mAb, 145-2C11. Administration of 145-2C11 led to rapid depletion of T cells from peripheral blood and suppression of skin graft rejection. However, depletion of T cells from spleen and lymph node was both delayed and incomplete. Full recovery of T cell number was dependent on the presence of a thymus, but treatment of thymectomized animals revealed that depletion was not the mechanism by which the mAb induced immunosuppression. Rather, alterations in TCR expression may play a more important role. TCR had modulated from T cells in spleen and lymph node early after treatment, and TCR expression remained subnormal for at least 51 days posttreatment. However, subnormal TCR expression alone could not fully explain the observed T cell dysfunction, inasmuch as a period of time existed after TCR re-expression during which T cells appeared to be anergic to CTL and MLR reactivity. These findings implicate T cell dysfunction as an important element in the induction of immunosuppression after anti-T3 administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286764

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses.

Authors:  A Elbe-Bürger; A M Mommaas; E E Prieschl; E Fiebiger; T Baumruker; G Stingl
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  PKM2-dependent metabolic reprogramming in CD4+ T cells is crucial for hyperhomocysteinemia-accelerated atherosclerosis.

Authors:  Silin Lü; Jiacheng Deng; Huiying Liu; Bo Liu; Juan Yang; Yutong Miao; Jing Li; Nan Wang; Changtao Jiang; Qingbo Xu; Xian Wang; Juan Feng
Journal:  J Mol Med (Berl)       Date:  2018-05-07       Impact factor: 4.599

Review 3.  Alpha beta T-lymphocyte depleted mice, a model for gamma delta T-lymphocyte functional studies.

Authors:  A Carbone; R Harbeck; A Dallas; D Nemazee; T Finkel; R O'Brien; R Kubo; W Born
Journal:  Immunol Rev       Date:  1991-04       Impact factor: 12.988

4.  Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.

Authors:  C Ferran; M Dy; K Sheehan; S Merite; R Schreiber; P Landais; G Grau; J Bluestone; J F Bach; L Chatenoud
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

5.  Sensitization of T-cell receptor-alpha beta+ T cells recovered from long-term T-cell receptor downmodulation.

Authors:  K Omoto; Y Y Kong; K Nomoto; M Umesue; Y Murakami; M Eto; K Nomoto
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

6.  Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival.

Authors:  Baharak Bahmani; Mayuko Uehara; Liwei Jiang; Farideh Ordikhani; Naima Banouni; Takaharu Ichimura; Zhabiz Solhjou; Georg J Furtmüller; Gerald Brandacher; David Alvarez; Ulrich H von Andrian; Kenji Uchimura; Qiaobing Xu; Ishaan Vohra; Osman A Yilmam; Yousef Haik; Jamil Azzi; Vivek Kasinath; Jonathan S Bromberg; Martina M McGrath; Reza Abdi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

7.  Local immunosuppressive therapy with monoclonal anti-T cell antibody on renal allograft survival in the rat.

Authors:  C J Lee; N Yoshimura; O Shiho; M Kita; T Oka
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

8.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors:  Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

9.  Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice.

Authors:  Devangi S Mehta; Rudy A Christmas; Herman Waldmann; Michael Rosenzweig
Journal:  Immunology       Date:  2010-01-06       Impact factor: 7.397

10.  Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Authors:  Simona Cernea; Kevan C Herold
Journal:  Clin Immunol       Date:  2010-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.